As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Kailera Therapeutics, Inc. The largest reported stake is BCPE Perseus Investor, LP's, at 20.27%. 5 filings are on record since April 23, 2026 (Schedule 13D, April 23, 2026).
Sell to companies like Kailera Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: RTW Investments, LP · Sole voting: 0 · Shared voting: 10,776,820 · Sole dispositive: 0 · Shared dispositive: 10,776,820 · SCHEDULE 13G, 2026-08-14
- · Reporting person: CPP Investment Board Private Holdings (4) Inc. · Sole voting: 0 · Shared voting: 7,304,688 · Sole dispositive: 0 · Shared dispositive: 7,304,688 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Jiangsu Hengrui Pharmaceuticals Co., Ltd. · Sole voting: 11,511,853 · Shared voting: 0 · Sole dispositive: 11,511,853 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-05
- · Holder: BCPE Perseus Investor, LP · Percent: 20.27% · SCHEDULE 13D
- · Holder: BCLS Fund IV Investments, L.P. · Percent: 17.43% · SCHEDULE 13D
Kailera Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2026-04-23. 5 holders' latest filing reports 5% or more of common stock, $0.00001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BCPE Perseus Investor, LP | 20.27% | 26,255,581 | SCHEDULE 13D, 2026-04-23 | 2026-04-16 |
| BCLS Fund IV Investments, L.P. | 17.43% | 22,583,268 | SCHEDULE 13D, 2026-04-23 | 2026-04-16 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 8.9% | 11,511,853 | SCHEDULE 13G, 2026-08-05 | 2026-06-30 |
| RTW Investments, LP | 8.3% | 10,776,820 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| CPP Investment Board Private Holdings (4) Inc. | 5.6% | 7,304,688 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Kailera Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Kailera Therapeutics, Inc. and the records around it.
Kailera Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. also filed stake reports on 1 other company: Braveheart Bio, Inc. (Nov 2026)
- CPP Investment Board Private Holdings (4) Inc. also filed stake reports on 12 other companies: ReNew Energy Global plc (Oct 2026), Americold Realty Trust, Inc. (Aug 2026), Chewy, Inc. (Aug 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), ORUKA THERAPEUTICS, INC. (Aug 2026)
Watch Kailera Therapeutics, Inc.
Get an email when Kailera Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kailera Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kailera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kailera Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 11,511,853 | 0 | 11,511,853 | 0 | SCHEDULE 13G, 2026-08-05 |
| RTW Investments, LP | 0 | 10,776,820 | 0 | 10,776,820 | SCHEDULE 13G, 2026-08-14 |
| Roderick Wong | 0 | 10,776,820 | 0 | 10,776,820 | SCHEDULE 13G, 2026-08-14 |
| CPP Investment Board Private Holdings (4) Inc. | 0 | 7,304,688 | 0 | 7,304,688 | SCHEDULE 13G, 2026-08-14 |
| Canada Pension Plan Investment Board | 0 | 7,304,688 | 0 | 7,304,688 | SCHEDULE 13G, 2026-08-14 |
The latest filing identifies Kailera Therapeutics, Inc. by CUSIP 482931102 and gives its principal executive office as 180 Third Avenue, 4th Floor, Waltham, MA 02451 (SCHEDULE 13G, 2026-08-14).
Purpose of Transaction (Item 4)
BCPE Perseus Investor, LP
The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Andrew Kaplan, a Partner of BCI, is a member of the Issuer's board of directors (the "Board"). The Reporting Person acquired the securities reported herein for investment purposes. In its capacity as a significant stockholder of the Issuer, the Reporting Person intends to take an active role in working with the Issuer's management and the Board on operational, financial and strategic initiatives. The Reporting Person reviews and intends to continue to review, on an ongoing and continuing basis, their investment in the Issuer. Depending upon the factors discussed below and subject to applicable law, the Reporting Person may from time to time acquire additional securities of the Issuer or sell or otherwise dispose of some or all of their securities of the Issuer. Any transactions that the Reporting Persons may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Issuer, the financial condition, results of operations and prospects of the Issuer, general economic, financial market and industry conditions, other investment and business opportunities available to the Reporting Person, tax considerations and other factors.Item 4 of the SCHEDULE 13D filed 2026-04-23
BCLS Fund IV Investments, L.P.
The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Adam Koppel, a Partner of BCLSI, is a member of the Issuer's board of directors (the "Board"). The Reporting Person acquired the securities reported herein for investment purposes. In its capacity as a significant stockholder of the Issuer, the Reporting Person intends to take an active role in working with the Issuer's management and the Board on operational, financial and strategic initiatives. The Reporting Person reviews and intends to continue to review, on an ongoing and continuing basis, their investment in the Issuer. Depending upon the factors discussed below and subject to applicable law, the Reporting Person may from time to time acquire additional securities of the Issuer or sell or otherwise dispose of some or all of their securities of the Issuer. Any transactions that the Reporting Persons may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Issuer, the financial condition, results of operations and prospects of the Issuer, general economic, financial market and industry conditions, other investment and business opportunities avialable to the Reporting Person, tax considerations and other factors.Item 4 of the SCHEDULE 13D filed 2026-04-23
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-04-23 | BCPE Perseus Investor, LP | 20.27% | SCHEDULE 13D |
| 2026-04-23 | BCLS Fund IV Investments, L.P. | 17.43% | SCHEDULE 13D |
| 2026-08-05 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 8.9% | SCHEDULE 13G |
| 2026-08-14 | CPP Investment Board Private Holdings (4) Inc. | 5.6% | SCHEDULE 13G |
| 2026-08-14 | RTW Investments, LP | 8.3% | SCHEDULE 13G |
Questions about who owns Kailera Therapeutics, Inc.
Who owns Kailera Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Kailera Therapeutics, Inc.: BCPE Perseus Investor, LP (20.27%, Schedule 13D, filed 2026-04-23), BCLS Fund IV Investments, L.P. (17.43%, Schedule 13D, filed 2026-04-23), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (8.9%, Schedule 13G, filed 2026-08-05), RTW Investments, LP (8.3%, Schedule 13G, filed 2026-08-14) and CPP Investment Board Private Holdings (4) Inc. (5.6%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Kailera Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Kailera Therapeutics, Inc. on this page are BCPE Perseus Investor, LP (20.27%), BCLS Fund IV Investments, L.P. (17.43%) and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (8.9%).
When did BCPE Perseus Investor, LP buy into Kailera Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BCPE Perseus Investor, LP on this page is the Schedule 13D, filed 2026-04-23, reporting 20.27%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Kailera Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.